GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chimerix Inc (NAS:CMRX) » Definitions » Cyclically Adjusted FCF per Share

CMRX (Chimerix) Cyclically Adjusted FCF per Share : $-1.37 (As of Dec. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Chimerix Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Chimerix's adjusted free cash flow per share for the three months ended in Dec. 2024 was $-0.215. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-1.37 for the trailing ten years ended in Dec. 2024.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was -1.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Chimerix was -1.00% per year. The lowest was -1.00% per year. And the median was -1.00% per year.

As of today (2025-05-11), Chimerix's current stock price is $8.54. Chimerix's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2024 was $-1.37. Chimerix's Cyclically Adjusted Price-to-FCF of today is .


Chimerix Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Chimerix's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chimerix Cyclically Adjusted FCF per Share Chart

Chimerix Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -1.33 -1.45 -1.44 -1.37

Chimerix Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.44 -1.44 -1.42 -1.41 -1.37

Competitive Comparison of Chimerix's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, Chimerix's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chimerix's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chimerix's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Chimerix's Cyclically Adjusted Price-to-FCF falls into.


;
;

Chimerix Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Chimerix's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=-0.215/133.1571*133.1571
=-0.215

Current CPI (Dec. 2024) = 133.1571.

Chimerix Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201503 -0.460 99.621 -0.615
201506 -0.566 100.684 -0.749
201509 -0.555 100.392 -0.736
201512 -0.731 99.792 -0.975
201603 -0.625 100.470 -0.828
201606 -0.277 101.688 -0.363
201609 -0.285 101.861 -0.373
201612 -0.211 101.863 -0.276
201703 -0.293 102.862 -0.379
201706 -0.278 103.349 -0.358
201709 -0.242 104.136 -0.309
201712 -0.259 104.011 -0.332
201803 -0.389 105.290 -0.492
201806 -0.295 106.317 -0.369
201809 -0.269 106.507 -0.336
201812 -0.164 105.998 -0.206
201903 -0.311 107.251 -0.386
201906 -0.271 108.070 -0.334
201909 -0.721 108.329 -0.886
201912 -0.057 108.420 -0.070
202003 -0.175 108.902 -0.214
202006 -0.127 108.767 -0.155
202009 -0.134 109.815 -0.162
202012 -0.144 109.897 -0.174
202103 -0.473 111.754 -0.564
202106 -0.149 114.631 -0.173
202109 -0.177 115.734 -0.204
202112 -0.392 117.630 -0.444
202203 -0.269 121.301 -0.295
202206 -0.121 125.017 -0.129
202209 0.081 125.227 0.086
202212 -0.227 125.222 -0.241
202303 -0.252 127.348 -0.263
202306 -0.162 128.729 -0.168
202309 -0.203 129.860 -0.208
202312 -0.164 129.419 -0.169
202403 -0.197 131.776 -0.199
202406 -0.198 132.554 -0.199
202409 -0.229 133.029 -0.229
202412 -0.215 133.157 -0.215

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Chimerix  (NAS:CMRX) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Chimerix Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Chimerix's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Chimerix Business Description

Industry
Traded in Other Exchanges
Address
2505 Meridian Parkway, Suite 100, Durham, NC, USA, 27713
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.
Executives
Allen S. Melemed officer: Chief Medical Officer C/O CHIMERIX, INC., 2505 MERIDIAN PARKWAY, SUITE 100, DURHAM NC 27713
David Jakeman officer: Principal Accounting Officer C/O CHIMERIX, INC.,, 2505 MERIDIAN PARKWAY, SUITE 100, DURHAM NC 27713
Michael Albert Alrutz officer: Principal Executive Officer 2530 MERIDIAN PARKWAY, 2ND FLOOR, DURHAM NC 27713
Michael T. Andriole officer: Chief Business Officer C/O ENDOCYTE, INC., 3000 KENT AVENUE, SUITE A1-100, WEST LAFAYETTE IN 47906
Fred A Middleton director 400 SOUTH EL CAMINO REAL STE 1200, SAN MATEO CA 94402-1708
Michael A. Sherman director, officer: Chief Executive Officer 3000 KENT AVE STE A1-100, WEST LAFAYETTE IN 47906
Martha J Demski director 7770 REGENTS ROAD SUITE 113-505, SAN DIEGO CA 92122
Robert J. Meyer director 2505 MERIDIAN PARKWAY, C/O CHIMERIX, INC, SUITE 100, DURHAM NC 27713
Cantex Pharmaceuticals, Inc. 10 percent owner 1792 BELL TOWER LANE, SUITE 222, WESTON FL 33326
Victoria Vakiener director C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Pratik S Multani director C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121
William Garrett Nichols officer: Chief Medical Officer C/O CANDEL THERAPEUTICS, INC., 117 KENDRICK ST SUITE 450, NEEDHAM MA 02494
M Michelle Berrey officer: Chief Medical Officer 303A COLLEGE ROAD EAST, PRINCETON NJ 08450
Ernest Mario director 20 FAIRMOUNT AVENUE, P.O. BOX 445, CHATHAM NJ 07928
Ed Greissing director 2505 MERIDIAN PARKWAY, C/O CHIMERIX, INC, SUITE 100, DURHAM NC 27713